Genentech is a biotechnology company that discovers, develops, manufactures, and commercializes medicines to treat patients with serious or life-threatening medical conditions. It creates multiple products on the market and a development pipeline.
The company became a member of the Roche Group in 2009. As part of their merger agreement, Roche and Genentech combined their pharmaceutical operations in the United States. Genentech’s South San Francisco campus now serves as the headquarters for Roche pharmaceutical operations in the United States. Genentech’s Research and Early Development section operates as an independent center within Roche.
|Jun, 2012||Rock Health||$4M / Private Equity||—|
|Jan, 2012||Constellation Pharmaceuticals||$95M / Series C (Lead)||David Goeddel|
|Oct, 2007||23andMe||$8.95M / Series A||Deborah Pascoe|
|Oct, 2006||Tolerx||$61M / Series D||—|
|Dec, 2005||GlobeImmune||$34.3M / Series B||—|
|Sep, 2005||Kereos||$19.5M / Series B||—|
|Sep, 2004||Cellective Therapeutics, Inc.||$27.5M / Series A||—|
|Mar, 2002||Tercica||$21.5M / Series A (Lead)||—|
Current Team (29)Update
1 Dna Way
South San Francisco, CA 94080